|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 31/519 | |
| A61K 31/7068 | |||
| A61P 9/10 |
| (11) | Number of the document | 3046627 |
| (13) | Kind of document | T |
| (96) | European patent application number | 14845184.2 |
| Date of filing the European patent application | 2014-09-15 | |
| (97) | Date of publication of the European application | 2016-07-27 |
| (45) | Date of publication and mention of the grant of the patent | 2019-10-23 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2014/055680 |
| Date | 2014-09-15 |
| (87) | Number | WO 2015/041987 |
| Date | 2015-03-26 |
| (30) | Number | Date | Country code |
| 201361879562 P | 2013-09-18 | US |
| (72) |
LEEPER, Nicholas J., US
WEISSMAN, Irving L., US
|
| (73) |
The Board of Trustees of the Leland Stanford Junior University,
Office of the General Counsel Building 170, Third Floor, Main Quad P.O. Box 20386, Stanford, CA 94305-2038,
US
|
| (54) | MODULATION OF EFFEROCYTOSIS PATHWAYS FOR TREATMENT OF ATHEROSCLEROTIC DISEASE |
| MODULATION OF EFFEROCYTOSIS PATHWAYS FOR TREATMENT OF ATHEROSCLEROTIC DISEASE |